Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Supplement—December 2022
SUPPLEMENT ISSUE
Clinical

Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru

Carmen S. ArriolaComments to Author , Giselle Soto, Matthew Westercamp, Susan Bollinger, Angelica Espinoza, Max Grogl, Alejandro Llanos-Cuentas, Eduardo Matos, Candice Romero, Maria Silva, Rachel Smith, Natalie Olson, Michael Prouty, Eduardo Azziz-Baumgartner, and Fernanda C. Lessa
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (C.S. Arriola, M. Westercamp, S. Bollinger, R. Smith, N. Olson, E. Azziz-Baumgartner, F.C. Lessa); Naval Medical Research Unit No. 6, Lima, Peru (G. Soto, A. Espinoza, M. Grogl, C. Romero, M. Silva, M. Prouty); Cayetano Heredia Hospital, Lima (A. Llanos-Cuentas); Arzobispo Loayza National Hospital, Lima (E. Matos)

Main Article

Table 2

COVID-19 vaccine effectiveness by number of doses received in a study on effectiveness of whole-virus COVID-19 vaccine among healthcare personnel, Lima, Peru, February 9–May 4, 2021*

Vaccination status†
COVID-19 cases

Non—COVID-19 cases

Vaccine effectiveness, % (95% CI)‡
Vaccinated
Unvaccinated
Vaccinated
Unvaccinated
Unadjusted
Adjusted
Received >1 vaccine dose 10 9 138 6 95 (84–99) 97 (88–99)
Fully vaccinated 5 9 36 6 91 (63–98) 95 (70–99)
Partially vaccinated 5 9 25 6 87 (45–97) 100 (88–100)

*Totals exclude persons with reactive SARS-CoV-2 serology (n = 106) and persons with positive COVID-19 test before February 9, 2021 (n = 17). †Persons who tested positive before vaccination date or before the 2-week period after vaccination were considered unvaccinated for the model. We defined full vaccination as the period starting 14 d after receipt of the second dose and partial vaccination as the period starting 14 d after receipt of the first dose. Participants not meeting these criteria were considered unvaccinated. The partial vaccination model only included persons who received 1 dose of the vaccine during the study period. ‡Adjusted for age, sex, exposure to COVID-19 patients, work in the intensive care unit, work in the emergency department, body-mass index, and time of follow-up in days.

Main Article

Page created: August 23, 2022
Page updated: December 11, 2022
Page reviewed: December 11, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external